S. 3267: Alzheimer's Screening and Prevention Act
This legislation, known as the Alzheimer's Screening and Prevention Act, aims to amend Medicare regulations to include coverage for early detection screening tests for Alzheimer's disease and related dementias. The main components of the bill are as follows:
Medicare Coverage Expansion
The bill proposes changes to the Social Security Act, specifically to Section 1861, to formally include Alzheimer's disease and related dementias early detection screening tests under Medicare. This would allow Medicare beneficiaries to access these tests at no additional cost.
Definition of Early Detection Screening Tests
Under the proposed law, an "Alzheimer’s disease and related dementias early detection screening test" is defined as a test conducted to identify the disease in its pre-symptomatic and early stages. To qualify for Medicare coverage, the tests must meet specific criteria, including:
- Getting approval or clearance from the Federal Food, Drug, and Cosmetic Act.
- Utilizing certain types of tests such as genomic sequencing blood tests or other equivalent testing methods.
Implementation Timeline
The coverage for these screening tests would begin on January 1, 2028, allowing time for the adaptation of necessary protocols and procedures within the healthcare system.
Payment Provisions
The bill also addresses payment for the new screening tests. It proposes amendments to Section 1833(h)(1)(A) of the Social Security Act to clarify that reimbursements will include the newly defined Alzheimer's screening tests.
Conclusion
In summary, if passed, this bill would increase access to early screening for Alzheimer’s and related dementias for those covered by Medicare, aiming to improve early diagnosis and intervention opportunities for patients at risk.
Relevant Companies
- AMGN - Amgen Inc. is involved in biotechnology and may be affected through the development and provision of diagnostic tests.
- ABBV - AbbVie Inc. is involved in biopharmaceuticals and could be impacted by the potential need for treatments following diagnosis from these screenings.
- BIIB - Biogen Inc. focuses on neuroscience and may find increased demand for products related to Alzheimer's treatment as a result of earlier detections.
This is an AI-generated summary of the bill text. There may be mistakes.
Sponsors
8 bill sponsors
Actions
2 actions
| Date | Action |
|---|---|
| Nov. 20, 2025 | Introduced in Senate |
| Nov. 20, 2025 | Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S8278-8279) |
Corporate Lobbying
0 companies lobbying
None found.
* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.
